Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Oil & Natural Gas Corporation Q2 Results 2025 on 31 Jan, 2025: profit falls by 25.2% YOY, profit at ₹10272.55 crore and revenue at ₹158329.1 crore ...

Company has reported net profit after tax of Rs 93.06 Crore in latest quarter.The company’s top management includes Mr.Sanjay Labroo, Mr.Masao Fukami, Mr.Gurvirendra Singh Talwar, Mr.Masahiro Takeda, ...